tirzepatide diarrhea and sulfur burps “Sulfur burps” in patients on GLP-1 therapies may be more than a minor side effect. Experts note these symptoms can reflect underlying gastrointestinal changes linked to the drugs’ mechanism of TMI- sulpher burps and diarrhea

Nationally, state Medicaid outfits are restricting GLP-1 coverage as list prices consistently climb alongside increasing demand

With respect to the prescription of semaglutide for ensuring weight management, Health Canada has given approval to the 2.4 mg of injection to serve as a measure to be implemented in addition to a reduced calorie diet and increased activity to manage weight in patients having: A BMI of 30 kg/m2 or higher (obesity) A BMI of 27 kg/m2 or higher (overweight) In addition to this, it is also expected that the patient should suffer from chronic weight-related issues, like dyslipidemia, hypertension, or obstructive sleep apnea

For effective weight loss, the target dose is 2.4 mg weekly , reached after the initial 16-week titration period

Critically, this does not affect the glucagon response to hypoglycemia as this effect is also glucose-dependent